XBiotech Inc. — Director's Dealing 2023

Feb 23, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: XBiotech Inc. (XBIT)
CIK: 0001626878
Period of Report: 2023-02-10

Reporting Person: HU ANGELA (Principle Financial Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	25500	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$19.00	2025-04-01	Common Stock (4500)		Direct
Employee Stock Option (right to buy)	$5.26	2029-01-03	Common Stock (5000)		Direct
Employee Stock Option (right to buy)	$10.36	2029-11-05	Common Stock (10000)		Direct
Employee Stock Option (right to buy)	$12.67	2031-11-18	Common Stock (10000)		Direct
Employee Stock Option (right to buy)	$3.84	2033-02-09	Common Stock (30000)		Direct

Footnotes

F1: On April 1, 2015 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in four equal portions in four years commencing as of April 1, 2016, with an expiry of ten years from the Grant Date.

F2: On January 4, 2019 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions in two years commencing as of January 4, 2020, with an expiry of ten years from the Grant Date.

F3: On November 6, 2019 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions in two years commencing as of November 6, 2020, with an expiry of ten years from the Grant Date.

F4: On November 19, 2021 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions in two years commencing as of November 19, 2022, with an expiry of ten years from the Grant Date.

F5: On February 10, 2023 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in four equal portions in two years commencing as of August 10, 2023, with an expiry of ten years from the Grant Date.